ArticleAAPS PharmSciTech2025
Development of Baicalin Loaded Soluplus Based Hydrogel Patch for Wound Dressing.
Article in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Antibacterial Mechanism of Baicalin and Its Solubilization Strategy.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo develop and optimize a baicalin-loaded soluplus-based hydrogel patch for enhanced wound healing applications.
methodsBaicalin-loaded hydrogel patches were formulated using freeze-thaw method and optimized through 3 × 2 factorial design with varying concentrations of PVA (1.0-2.0 g) and Soluplus (0.33-0.66 g). The patches were characterized for physicochemical properties, ex vivo permeation, stability, skin irritation potential, and wound healing efficacy in rat models.
resultsSolubility studies revealed poor aqueous solubility of baicalin (0.052 mg/ml) while FTIR confirmed drug-excipient compatibility. The optimized formulation BF6 (PVA 2.0 g, Soluplus 0.495 g) demonstrated superior folding endurance (378 ± 16.52), drug content (90.23 ± 1.32%), and swelling index (168.42 ± 5.93%). Ex vivo permeation studies showed enhanced baicalin delivery (93.24 ± 3.94% at 12 h) with a flux of 5.73 ± 0.28 mg/cm
conclusionThe optimized baicalin-loaded soluplus-based hydrogel patch offers a promising approach for chronic wound management with enhanced healing rates, excellent stability, and safety profile. This first-in-class baicalin-Soluplus combination addresses the challenges of baicalin's poor solubility through systematic factorial optimization. while providing controlled drug delivery and optimal wound microenvironment, presenting significant potential for clinical translation in advanced wound care therapy. Future mechanistic studies are warranted to elucidate molecular healing pathways.
Indexed as
Identifiers
41219576What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.